Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer in a Phase 2 Study.

Bauer TM, Martini JF, Besse B, Lin CC, Soo RA, Riely GJ, Wang IM, Toffalorio F, Shepard DA, Usari T, Hamilton P, Camidge DR, Kao S, Chiari R, Gadgeel S, Felip E, Shaw AT, Solomon BJ

Open source

DOI: 10.1016/j.jtho.2026.104202
Published: 2026 Sep 16
Container: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtho.2026.104202,
  title = {Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer in a Phase 2 Study.},
  author = {Bauer TM and Martini JF and Besse B and Lin CC and Soo RA and Riely GJ and Wang IM and Toffalorio F and Shepard DA and Usari T and Hamilton P and Camidge DR and Kao S and Chiari R and Gadgeel S and Felip E and Shaw AT and Solomon BJ},
  year = {2026},
  journal = {Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  doi = {10.1016/j.jtho.2026.104202},
  url = {https://doi.org/10.1016/j.jtho.2026.104202}
}

RIS

TY  - JOUR
TI  - Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer in a Phase 2 Study.
AU  - Bauer TM
AU  - Martini JF
AU  - Besse B
AU  - Lin CC
AU  - Soo RA
AU  - Riely GJ
AU  - Wang IM
AU  - Toffalorio F
AU  - Shepard DA
AU  - Usari T
AU  - Hamilton P
AU  - Camidge DR
AU  - Kao S
AU  - Chiari R
AU  - Gadgeel S
AU  - Felip E
AU  - Shaw AT
AU  - Solomon BJ
PY  - 2026
JO  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
DO  - 10.1016/j.jtho.2026.104202
UR  - https://doi.org/10.1016/j.jtho.2026.104202
ER  -

APA

TM, B., JF, M., B, B., CC, L., RA, S., GJ, R., IM, W., F, T., DA, S., T, U., P, H., DR, C., S, K., R, C., S, G., E, F., AT, S., & BJ, S. (2026). Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer in a Phase 2 Study.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. https://doi.org/10.1016/j.jtho.2026.104202

Source records

pubmed · retrieved 2026-09-26T06:08:04.727Z